Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits
- PDF / 534,300 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 170 Views
COVID-19
Investigation of Anti-SARS-CoV-2 IgG and IgM Antibodies in the Patients with COVID-19 by Three Different ELISA Test Kits Masayuki Nagasawa 1,2 & Yoshimi Yamaguchi 3 & Maki Furuya 3 & Yui Takahashi 3 & Reiko Taki 4 & Kaoru Nagata 5 & Shinichiro Suzaki 6 & Masayuki Kurosaki 7 & Namiki Izumi 8 Accepted: 10 July 2020 # Springer Nature Switzerland AG 2020
Abstract We examined anti-SARS-CoV-2 IgG and IgM antibodies in 45 serum samples from 26 patients with COVID-19, who were admitted in our hospital by using three different ELISA kits. All patients had pneumonia at admission, and 7 patients required mechanical ventilator support and grouped in severe case. Anti-SARS-CoV-2 IgG and IgM antibodies turned to be partially positive between the 6th and 10th days, more than 84% positive between the 11th and 15th days, and 100% after the 16th day. One ELISA kit revealed poorer sensitivity for anti-SARS-CoV-2 IgM antibody. Negative conversion of IgM antibody was not observed in the 30th day in our cohort. All three ELISA kits showed no false positive reaction for negative serum samples. Between severe and moderate cases, there was no significant difference in the trends of anti-SARS-CoV-2 IgG and IgM antibody. Keywords SARS-CoV-2 . COVID-19 . ELISA . Antibody
Introduction In December 2019, novel coronavirus (SARS-CoV-2) infection (COVID-19) has emerged in China and spread with amazing speed worldwide and resulted in the pandemic [1]. The pandemic has deep and serious impact not only on the medical service but also on socio-economic activity worldwide. More than 7 million people were infected, and more than 400,000 people were dead in the world at the moment of early June 2020 [2]. In addition to the absence of specific treatment and effective vaccine, it makes infection control very difficult that there are many infected patients with no
symptom and slight illness, who spread virus into the society insidiously. The Japanese Government pronounced emergency declaration on April 7, and infection eventually burnt down in 2 months. However, the problem in the future infection control for the 2nd wave of COVID-19 is not solved fundamentally yet. In this context, the epidemiological analysis in the society by using the test for antibodies is expected to give important information for the future public health strategy. According to the concept above, we have investigated antiSARS-CoV-2 antibody in hospitalized infected patients in our
This article is part of the Topical Collection on Covid-19 * Masayuki Nagasawa [email protected] 1
2
3
Department of Infection Control, Musashino Red Cross Hospital, 1-26-1, Kyonan-cho, Musashino City, Tokyo 180-8610, Japan Department of Pediatrics, Musashino Red Cross Hospital, 1-26-1, Kyonan-cho, Musashino City, Tokyo 180-8610, Japan Department of Laboratory, Musashino Red Cross Hospital, Musashino City, Japan
4
Department of Respiratory Medicine, Musashino Red Cross Hospital, Musashino City, Japan
5
Department of General Medicine, Musashino Red Cross Hospital, Musashino City, Ja
Data Loading...
